Phase I Safety and Tolerability Study of NWRD08 in HPV-16 and/or HPV-18 Related Cervical High-grade Squamous Intraepithelial Lesion (HSIL) Patients
Latest Information Update: 27 Feb 2024
At a glance
- Drugs NWRD-08 (Primary)
- Indications Human papillomavirus infections
- Focus Adverse reactions
- Sponsors Newish Technology (Beijing)
- 27 Feb 2024 New trial record